Clinical Therapeutics/New Technology-Non-Insulin Injectables

Clinical Therapeutics/New Technology-Non-Insulin Injectables

Open Access
Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
Yasser Albogami, Kenneth Cusi, Michael J Daniels, Yu-Jung J. Wei, Almut G. Winterstein

Diabetes Care Aug 2021, 44 (8) e167; DOI: 10.2337/dci21-0024
Open Access
Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
Dinah Foer, Katherine N. Cahill

Diabetes Care Aug 2021, 44 (8) e165-e166; DOI: 10.2337/dc21-0904
Open Access
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
Guillaume Marquis-Gravel, Jean-Claude Tardif

Diabetes Care Jun 2021, 44 (6) 1252-1253; DOI: 10.2337/dci20-0076
Open Access
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Juan P. Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G. Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M. Angelyn Bethel, David A. Cox

Diabetes Care Mar 2021, 44 (3) 765-773; DOI: 10.2337/dc20-1473
Open Access
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
Dario Giugliano, Miriam Longo, Paola Caruso, Rosa Di Fraia, Lorenzo Scappaticcio, Maurizio Gicchino, Michela Petrizzo, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito

Diabetes Care Jun 2021, 44 (6) 1353-1360; DOI: 10.2337/dc20-2623
Open Access
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
Jessica A. Huthmacher, Juris J. Meier, Michael A. Nauck

Diabetes Care Sep 2020, 43 (9) 2303-2312; DOI: 10.2337/dc20-0498
Open Access
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
Matthew J. Crowley, Darren K. McGuire, Anastasia-Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A. Saevereid, Subodh Verma, John B. Buse

Diabetes Care Sep 2020, 43 (9) e108-e110; DOI: 10.2337/dc20-0437
You have access
Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial
Christopher K. Rayner, Linda E. Watson, Liza K. Phillips, Kylie Lange, Michelle J. Bound, Jacqueline Grivell, Tongzhi Wu, Karen L. Jones, Michael Horowitz, Ele Ferrannini, Domenico Tricò, Silvia Frascerra, Andrea Mari, Andrea Natali

Diabetes Care Aug 2020, 43 (8) 1813-1821; DOI: 10.2337/dc20-0190
Open Access
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
Geremia B. Bolli, Francesca Porcellati, Juris J. Meier

Diabetes Care Oct 2020, 43 (10) 2333-2335; DOI: 10.2337/dci20-0038
Open Access
GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
Alexander S. Christensen, Sofie Hædersdal, Heidi Storgaard, Kathrine Rose, Nina L. Hansen, Jens J. Holst, Torben Hansen, Filip K. Knop, Tina Vilsbøll

Diabetes Sep 2020, 69 (9) 1989-2002; DOI: 10.2337/db20-0074

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Non-Insulin Injectables

Pages

Navigation

Information

ADA Journals

Other ADA Resources